Excitatory and inhibitory neurotransmission is chronically altered following perinatal NMDA receptor blockade Abstract N-methyl-d-aspartate (NMDA) receptor blockade in rodents induces behavioural and neurochemical changes reminiscent of schizophrenia symptoms and pathology. To examine how NMDA receptor blockade affects glutamatergic and GABAergic pathways when administered during early brain development, [3H]MK-801 and [3H]muscimol binding to NMDA and GABAA receptors was examined at four timepoints following injections of phencyclidine (PCP) or saline on postnatal days (PN)7, 9 and 11.
INTRODUCTION

Glutamate, predominantly through its actions on N-methyl-D-aspartate
receptors, plays a key role in brain developmental processes such as neuronal migration, synaptogenesis and synaptic plasticity (McDonald and Johnston 1990; Pearce et al. 1987) . The timing of expression of glutamate receptors appears to be crucial for normal brain development, since changes in the activity of glutamate receptors may interfere with these processes (Ritter et al. 2001; Ritter et al. 2002) .
During development in the rat, particularly postnatal days (PN)7-14, the brain is highly sensitive to the toxic effects of modulation of the NMDA receptor (Haberny et al. 2002) , which may relate to the increased expression of specific NMDA receptor subunits (Mitani et al. 1998) . Given the important role of the NMDA receptor in brain developmental processes, antagonism of this receptor could have severe long-term detrimental effects such as reduced and/or non-functional neuronal connections (Behar et al. 1999 ).
In rodents, treatment with NMDA receptor antagonists such as phencyclidine (PCP) and MK-801 during the perinatal period induces neuronal apoptosis (Fredriksson et al. 2004; Hansen et al. 2004; Harris et al. 2003; Ikonomidou et al. 1999; Wang et al. 2001 ). In the long-term, perinatal NMDA receptor blockade impairs cognitive function (Andersen and Pouzet 2004; Sircar 2003; Stefani and Moghaddam 2005; Wang et al. 2001; Wiley et al. 2003) , sensorimotor gating (Harris et al. 2003; Wang et al. 2001; Wang et al. 2003) and locomotor activity (du Bois et al. 2008b; Facchinetti et al. 1993; Wang et al. 2001) , which are particularly relevant to schizophrenia symptoms and pathology. Abnormal expression of neurotransmitter receptors du Bois et al. including dopamine D2 (du Bois et al. 2008a; Sircar and Soliman 2003) and NMDA (Harris et al. 2003; Wang et al. 2001; Wilson et al. 1998 ) is a further long-term consequence of perinatal NMDA receptor blockade. Recently it was shown that perinatal PCP treatment caused a selective loss of parvalbumin-containing (GABAergic) neurons in the cortex of rats at adulthood (Wang et al. 2007 ).
Hypofunction of NMDA receptors has been implicated in schizophrenia, since NMDA receptor anatgonists such as PCP and ketamine mimic schizophrenia symptoms so well in healthy individuals and strongly exacerbate symptoms in schizophrenia patients (Javitt and Zukin 1991 (Newell et al. 2005; Zavitsanou et al. 2002) , superior temporal gyrus (Nudmamud and Reynolds 2001) and putamen (Kornhuber et al. 1989 ) of schizophrenia patients versus controls, while binding was reported as unchanged in other areas including the frontal and entorhinal cortices, hippocampus and amygdala (Kornhuber et al. 1989 ).
Conversely, decreased NMDA receptor binding has been observed in the hippocampus (Dean et al. 1999) , using [ 3 H]TCP.
Findings also point to a deficit in GABAergic transmission in schizophrenia.
Decreased GAD 67 , a marker for GABAergic terminals, has been found in the prefrontal cortex (Akbarian et al. 1995; Guidotti et al. 2000; Volk et al. 2000) .
Reductions of GABAergic interneurons have been found in anterior cingulate and prefrontal cortices and hippocampus (Benes et al. 1998; Benes et al. 1991) . Moreover, reductions of parvalbumin-containing interneurons have been reported in superficial du Bois et al.
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layers of the prefrontal cortex (Beasley and Reynolds 1997; Reynolds et al. 2002) .
Deficits in GABA synthesis and release may therefore contribute to the observed increase in [ 3 H]muscimol binding in several brain regions (Benes et al. 1992; Benes et al. 1996; Deng and Huang 2006; Newell et al. 2007 ).
Along with perinatal PCP treatment of rodents, another developmental model of schizophrenia (prenatal methylazoxymethanol acetate (MAM) administration) has shown decreased parvalbumin-containing interneurons (Lodge et al. 2008) , suggesting that common targets and pathways contribute to the schizophrenia-like pathology in these animal models. The fact that these models alter the expression of parvalbumincontaining (GABAergic) neurons has important construct validity, as disinhibition of pyramidal neurons from reduced GABAergic activity is thought to contribute to schizophrenia pathology (Lisman et al. 2008 Pups were sexed on PN7 and litters were assigned to PCP or saline groups (5 litters/group). Male pups were kept in the litters until weaning but were not treated.
Pups were weaned at PN24-28 and were then housed in pairs. Female rats were used because the literature shows that treating female rat pups on PN7, 9 and 11 with PCP produces apoptosis and alterations in sensorimotor gating, motor activity and working memory (Wang et al. 2001; Wiley et al. 2003) , all of which have particular relevance to schizophrenia symptoms and pathology. This study was approved by the Animal 
Perinatal PCP treatment
On PN7, 9 and 11, pups were given a subcutaneous injection of 10 mg/kg phencyclidine hydrochloride (Sigma, Castle Hill, NSW, Australia) or 0.9% NaCl at a volume of 1 ml/kg. Six rats from each group (PCP and control) were sacrificed at four different time-points (24 hr, 1 week, 3 weeks or 12 weeks) following their last injection for biochemical analyses, representing juvenile (PN12 and 18), adolescent (PN32) and adult (PN96) ages.
Histology
Rats were sacrificed by carbon dioxide asphyxiation and brains were removed and frozen in liquid nitrogen immediately after extraction. Brain tissue was kept at -80°C 
NMDA receptor binding
The method for NMDA receptor binding was taken from Newell et al. (2005) .
Sections were incubated at room temperature for 2.5 hr in 30 mM N-2-hydroxyethyl piperazine-N'-2-ethanesulphonic acid (HEPES) buffer, pH 7.5, containing 100 mM glycine, 100 mM glutamate, 1 mM ethylenediaminetetraacetic acid (EDTA) and 20
nM [ mM EDTA (pH 7.5). Autoradiographic images for NMDA receptor binding were taken using a Beta-Imager TM camera (BioSpace, Paris, France). Sections were scanned for 3.5 hr at a high-resolution setting. A series of sections with known amount of radioactivity were used as standards in all scans. Quantitative analysis of these images was performed using the program β-Image Plus (version 4, BioSpace).
GABA A receptor binding
The method for GABA A receptor binding followed that of Newell et al. (2007) .
Sections were pre-incubated three times for 5 min at 4ºC in 50 mM Tris-citrate (pH 7). Sections were then incubated for 45 min at 4ºC in the same buffer containing 3 nM du Bois et al.
[ 3 H]muscimol (specific activity 29.5 Ci/mmol; PerkinElmer, USA). Non-specific binding was determined by the addition of 100 µM GABA to adjacent sections.
Following incubation, sections were rinsed four times for 2 s in 4ºC buffer and dried in a stream of cool air. Sections were opposed to Kodak BioMax MR film with
Amersham microscales for 12 weeks. Autoradiographs were developed using Kodak GBX developer and fixed with Kodak GBX fixer. Autoradiographic images were captured and analysed using a computer-assisted image analysis system, MultiAnalyst, connected to a GS-690 Imaging Densitometer (Bio-Rad, California).
Quantification
A set of sections from each age and treatment group were stained with cresyl violet for confirmation of anatomical structures. Specific binding was calculated by subtracting non-specific binding from total binding. Non-specific binding was less than 30% of total binding. The data presented is the average of three brain sections from each of the six rats per group. Areas quantified included the prefrontal and anterior cingulate cortices, the ventral thalamus and hippocampus. Sub-regions of the hippocampus (CA1-3) were quantified, but no differences were found so the mean of the sub-regions was used in the results.
Statistical Analyses
Statistical analyses were performed using SPSS (version 15.0, SPSS Inc., Chicago). 
RESULTS
NMDA receptor binding across developmental time-points Prefrontal cortex
In the prefrontal cortex, there were significant main effects of age (F 3, 34 (Fig. 1A) . At PN96 there was no change compared to controls.
Anterior cingulate cortex
The anterior cingulate cortex also showed significant main effects of age (F 3, 37 = 191.29, p<0.001) Fig. 2A , B) compared to controls.
Thalamus
In the thalamus there were significant main effects of age (F 3, 40 = 263.7, p<0.001) and treatment (F 1, 40 =95.0, p<0.001), as well as interaction between the two factors (F 3, 40 = 12.7, p<0.001) . The control group displayed a temporal pattern whereby binding increased from PN12 to PN18 (p<0.001) then increased slightly more from PN32 to PN96 (p<0.05). The PCP-treated group also showed a large increase in binding from PN12 to PN18 (p<0.001), but this was then followed by a further increase at PN32 (p<0.01) with no change at PN96. In terms of treatment effects, there were increases in NMDA receptor binding at PN18 (12%), PN32 (29%) and PN96 (22%) compared to the control group (p's <0.001; Fig. 1C ).
Hippocampus
In the hippocampus there was a main effect of age (F 3,40 were no differences at the other time-points (Fig. 1E) .
Anterior cingulate cortex
In the ACC, there was a significant main effect of age (F 3,39 = 30.5; p<0.001) but not treatment, although there was a significant interaction between the two factors (F 3,39 = 15.0; p<0.001). When looking at the temporal pattern of GABA A receptor binding, control rats showed increased binding levels at PN18 (p<0.05), followed by a further increase at PN96 (p<0.01). In PCP-treated rats, GABA A receptor binding increased with age until PN32 (p<0.05), after which it significantly declined (p<0.001). Similar to the prefrontal cortex, GABA A receptor binding levels were significantly elevated (59%; p<0.001; Fig. 2C , D) in PCP-treated rats compared to controls at PN32, while there were no significant differences at other time-points (Fig. 1F) .
Thalamus
In the thalamus, there were significant main effects of age (F 3,34 PCP-treated rats compared to controls at all ages from PN18 onwards (Fig 1G) .
Hippocampus
In the hippocampus, there were significant main effects of age (F 3,34 (Fig. 3A, B) . In the thalamus, there was Fig. 3C ).
Finally, in the hippocampus, there was a significant positive correlation between NMDA and GABA A receptor binding at PN96 (r=0.919, p<0.001; Fig3D) .
DISCUSSION
The present study examined how NMDA and GABA A receptor binding are altered during the course of brain development following perinatal PCP treatment. We found that the pattern of change of these two systems was remarkably similar and highly correlated in all regions examined, highlighting the close relationship between the two systems. In PCP-treated rats, the thalamus and hippocampus both showed increased NMDA and GABA A receptor binding levels compared to controls, which were still evident at adulthood. The prefrontal and anterior cingulate cortices also showed increased binding of these two receptors, mainly at adolescence. (Facchinetti et al. 1993; Insel et al. 1990; Morin et al. 1989; Xia and Haddad 1992) .
Perinatal administration of NMDA receptor antagonists is known to induce massive increases in neuronal apoptosis (Fredriksson et al. 2004; Hansen et al. 2004; Harris et al. 2003; Ikonomidou et al. 1999; Wang et al. 2001) . In fact, using corticostriatal slices from PN7 rats, Wang et al. (2005) showed that PCP-induced apoptosis required upregualtion of NR1 and NR2A polypeptides. Co-incubation of PCP with an antisense oligodeoxynucleotide specific to the NR1 and NR2A mRNAs prevented both PCP-induced NR1 and NR2A upregulation and cortical DNA fragmentation. We A loss of or decreased stimulation GABAegic cells would presumably lead to disinhibition and over-excitation of pyramidal neurons. In the prefrontal cortex, a reduction in GABAergic transmission would reduce inhibitory inputs to pyramidal neurons, resulting in less filtering of noise, which could contribute to cognitive deficits seen in this model (Andersen and Pouzet 2004; Wang et al. 2001; Wiley et al. 2003) . Similarly, in schizophrenia, disinhibition of pyramidal neurons through a loss of GABAergic outputs is thought to contribute to symptoms of the disorder (Lisman et al. 2008 ). In the hippocampus, disinhibition of pyramidal neurons could elevate activity of ventral tegmental area (VTA) neurons. This elevation of VTA activity has been shown to occur in another schizophrenia animal model which has deficits in hippocampal interneurons caused by prenatal methylazoxymethanol acetate (MAM) administration, and can be reversed by inactivating the subiculum (Lodge and Grace 2007) . This is consistent with our previous findings of elevated tyrosine hydroxylase mRNA expression in the VTA, and decreased D2 receptor binding in striatum following perinatal PCP treatment, which we suggest reflects increased dopamine output from the VTA (du Bois et al. 2008a ).
Our finding that perinatal blockade of NMDA receptors may lead to long-term deficits in glutamatergic and GABAergic neurotransmission is relevant to schizophrenia pathology and treatment. Interestingly, co-administering agents that enhance GABAergic transmission with antipsychotic drugs provide more effective therapy to schizophrenia patients than antipsychotics alone (Casey et al. 2003; Wassef et al. 2000) , including in treatment-resistant patients (Dursun and Deakin 2001; Tiihonen et al. 2003) . Moreover, agents which enhance NMDA receptor channel activity such as agonists of the glycine binding site (eg. D-cycloserine, glycine and Ddu Bois et al.
serine), and sarcosine, a glycine transport inhibitor, have had good success in treating when co-administered with antipsychotic drugs (Coyle and Tsai 2004; Lane et al. 2006; Tsai et al. 2004 ). In addition, it has been recently shown that an mGlu2/3 agonist is effective alone in treating symptoms (Patil et al. 2007) , and part of the effect may be related to enhancement of postsynaptic NMDA receptor function (Tyszkiewicz et al. 2004) . Recently, Andersen and Pouzet (2004) 
